US20080085868A1

US20080085868A1 - Monoclonal Antibody 3F1H10 Neutralising VHSV (Viral Haemorrhagic Septicaemia Virus)

Info

Publication number: US20080085868A1
Application number: US11/829,201
Authority: US
Inventors: Christopher Secombes; Charles Cunningham; Niels Lorenzen
Original assignee: Dianova AS; Danmarks FodevareForskning; University of Aberdeen
Current assignee: Dianova AS; Danmarks FodevareForskning; University of Aberdeen
Priority date: 1999-09-20
Filing date: 2007-07-27
Publication date: 2008-04-10
Also published as: US7265095B1; ZA200202246B; WO2001021800A1; EP1218507A1; AU7673000A; AU782805B2

Abstract

The present invention relates to a non-infectious nucleic acid (RNA and DNA) construct constructed to express a recombinant antibody or antibody fragment in a host cell. The antibody molecule confers protection to the host against a pathogen, allergen or toxin. The host may be any animal including a human.

Description

The present invention relates to a non-infectious nucleic acid (RNA and DNA) construct constructed to express a recombinant antibody or antibody fragment in a host cell. The antibody molecule confers protection to the host against a pathogen, allergen or toxin. The host may be any animal including a human.
Passive immunization by injection of homologous or heterologous serum-antibodies is routinely used in humans for immunoprophylaxis of people traveling to foreign regions involving risk of exposure to exotic pathogens. In animals a similar strategy may be employed for protection of valuable specimens, but is generally too expensive for routine veterinary use. Passive immunisation of animals against infectious diseases is thus mostly done on an experimental basis with the aim of studying the function of structures such as antibodies in vivo and relating the results to in vitro experiments.
During the recent decade, diverse technologies for the in vitro production of antibodies by the use of recombinant DNA technology has been developed. The smallest functional recombinant antibody combining the actions of the heavy (H) and light (L) polypeptide chains as in the native molecule has proved to be the single chain variable-fragment construct (single chain FV). The single chain FV construct is composed of the variable parts of the H and L chains connected by a flexible spacer region. Such molecules have been used in various studies including virus neutralisation, cancer-immunotherapy and recently also in the form of DNA vaccines where plasmids encoding anti-idiotype single chain FV antibodies have proved able to induce an antigen-specific immune response. However, direct establishment of protective immunity to infectious diseases by prophylactic treatment with plasmid DNA carrying single chain FV genes encoding protective antibodies has not been described.
An object of the present invention is to provide a non-infectious nucleic acid construct which can produce an antibody molecule in vivo thereby conferring immunity to a disease.
A further object of the present invention is to provide a method of establishing immunity against a pathogen.
A yet further object of the present invention is to provide a method of therapy for animals which have a deficient immune system.
An additional object of the present invention is to provide a method of therapy for an animal suffering from an allergic reaction or a method of preventing an allergic reaction.
For avoidance of doubt it should be noted that the word “animal” includes but is not restricted to mammals including humans.
According to an embodiment of the present invention there is provided a nucleic acid construct encoding a recombinant antibody molecule, said construct being adapted for the in vivo establishment of a protective immunity to an infectious disease in an animal.
According to a further embodiment of the present invention there is provided a nucleic acid construct encoding a recombinant antibody molecule, said construct is formulated for the in vivo prevention of an allergic reaction to an allergen in an animal.
According to a yet further embodiment of the present invention there is provided a nucleic acid construct encoding a recombinant antibody molecule, wherein said construct is formulated for the in vivo prevention of a reaction caused by the presence of a toxic substance in an animal.
The term recombinant antibody molecule encompasses a full size antibody, a single chain variable fragment or any part of an antibody which can recognise an antigen. In this connection, conveniently the antibody fragment does not have to be single chain. However, in some embodiments it is single chain.
It has now been found that the intramuscular injection of a nucleic acid construct, in the form of a plasmid, encoding a virus-neutralising single chain antibody fragment can mediate in vivo expression of antibodies which protect an animal against a possibly lethal exposure to a virus. This has been established in an experimental model which involves a fish rhabdovirus called viral haemorrhagic septicaemia virus (VHSV) in the rainbow trout (Oncorhynchus mykiss) as a host species.
According to a further embodiment of the present invention there is provided a nucleic acid construct, such as a plasmid, comprising an expression vector and a gene sequence for heavy and/or light chain variable domains of an antibody.
Preferably the heavy and light chain variable domains are linked by a linker sequence in order that they form what is known in the art as a single chain variable-fragment.
It is thought that the antibody fragment as expressed in and secreted from a host cell carrying the vector will act with the same specificity as a natural antibody would in the presence of a substance which it recognises. In this connection, for example, if the heavy and/or light chain variable domain were derived from a monoclonal antibody raised against dengue virus then if dengue virus infected a host who had received a nucleic construct expressing a single chain variable fragment produced from the heavy and light chain of the monoclonal antibody, the fragment would recognise cells infected with the dengue virus or the dengue virus particle itself and bind thereto thereby neutralising or inhibiting the virus and/or giving the host time to mount an immune response against the virus.
In preferred embodiments the expression vector is made for eukaryotic expression and/or is non infectious. For example, a bacterial plasmid, or a smaller DNA fragment carrying the variable fragment antibody gene within a eukaryotic expression operon including regulatory elements such as an enhancer, promoter and polyadenylation signal could be used. Alternatively, stabilised messenger RNA including a positive strand transcript of the variable-fragment antibody gene with translation signals may be employed.
The antibody fragment genes can be cloned by any method known to those skilled in the art, for example from hybridoma cells or directly from B-lymphocytes from immunized individuals. Nucleic acid constructs encoding protective antibody fragments can be prepared against any important pathogen/disease causing agent in animals including pathogens against which vaccines are not available or have proved insufficient. Furthermore, as a result of veterinary regulations, use of live vaccines may not be allowed. In such cases an alternative prophylactic measure would have to be taken. Such a measure could be the administration of the nucleic acid construct of the present invention. A list of possible pathogens is given below; this list is not intended to be exhaustive.
Viral haemorrhagic septicaemia virus (fish)
Infectious haematopoietic necrosis virus (fish)
Infectious salmon anemia virus (fish)
Infectious pancreatic necrosis virus (fish)
Nodaviruses (fish)
Renibacterium salmoniarum (fish)
Pasteurella (fish)
Ichthyopthtirius mulitifiliis (fish)
NewCastle disease virus (fowl)
Infectious bursal disease virus (fowl)
Bovine respiratory syncytial virus (cattle)
Bovine virus diarrhoea virus (cattle)
Porcine reproductive and respiratory syndrome virus (pigs)
Pseudorabiesvirus (pigs)
Equine herpes virus 1 (horses)
Plasmocytosis virus (mink)
Rabies virus (dogs)
Feline leukemia virus (cats)
Foot and mouth disease (cattle)
Human immune deficiency virus (human)
Hepatitis A virus (human)
Borrelia sp. (human)
Plasmodium sp. (human)
Rabies virus (human)
Epstein-Barr virus (human)
In case of humans with either a congenital or acquired immunodeficiency, vaccines will generally be insufficient. In such cases, administration of a number of nucleic acid constructs according to the present invention encoding antibodies against a broad spectrum of pathogens may be considered.
For the purpose of prevention of allergic relations induced by IgE response, administration of nucleic acid constructs mediating expression of an allergen-specific recombinant antibody may be used to competitively inhibit binding of the allergen to the IgE molecules in the host. Alternatively gene constructs encoding anti-IgE antibodies may be used to interfere with the interaction between IgE and mast cells in the allergic individual.
Administration of antibody gene constructs encoding antibodies to toxins or venoms can be used for the prophylactic treatment of individuals periodically being in high risk of exposure to toxic organisms. The venoms could, for example, be from snakes or spiders.
Conveniently the construct further comprises a gene encoding a signal sequence for the secretion of the product encoded by the gene sequence. The signal sequence will allow the product of the gene sequence to be secreted from a cell in which the gene has been expressed, into the blood so that the product of the gene sequence can circulate therein. For example, the genes for the signal sequence of either rainbow trout transforming growth factor beta (TGF-beta), or murine Ig kappa-chain can be added to the 5′ end of a gene to be administered to the fish. Other secretion signals, preferably of homologous origin to the host species may be employed. Examples of genes which encode proteins which act as secretion signals include the gene for immunoglobulin heavy and light chain secretion signals or other glycoprotein secretion signals. Preferably, the secretion signal should include a proteolytic cleavage site ensuring removal of the signal peptide before secretion of the antibody fragment.
Preferably the construct further comprises a known gene sequence which encodes a short peptide sequence that can be used to identify transfected cells. Such a gene sequence can be attached to the 3′ end of the gene. Examples of such a sequence include a human kappa light chain construct or sequence encoding a six histidine residue. In both cases, an antibody specifically recognising the expressed peptide is commercially available.
The construct according to the present invention may be delivered by any suitable method, such as by injection (e.g. intramuscularly), by a spray on a mucosa surface (e.g. intranasally), by particle bombardment on skin/dermis through use of a gene gun, by electroporation or by uptake by an animal from an aqueous environment. In this connection, the plasmid may be encased in a liposome for administration to an animal. The construct may be administered to the animal topically, through inhalation or orally. For oral administration the construct should be protected from degradation by proper encapsulation.
It is preferred that in a composition or formulation for administration of the constructs there are present genes encoding the heavy and/or light chain variable fragments against several different epitopes or an variable fragment antibody gene expression library against a given pathogen. In this connection, the various fragments may be provided on one plasmid or they may be provided on several different gene constructs which are all present in the same formulation or other method of administration. In the alternative, each plasmid may have to be administered separately.
The invention also provides for a method for treating an animal, for example a mammal or a fish which comprises administering thereto a plasmid or other nucleic acid construct encoding a protective antibody fragment as previously described.
The invention thus provides for a method of therapy for an animal which has a deficient immune system.
The invention also provides for a therapeutic composition comprising the plasmid as previously described and a pharmaceutically acceptable diluent or carrier therefor. The composition may be formulated such that it is in the form of, for example, a vaccine, dosage form, cream, ointment, liquid or paint.
The invention will now be described by way of illustration only with reference to the following Example and Figures.
FIG. 1 shows a schematic drawing of the pcDNA3 plasmid with a single chain antibody (ScAb) gene construct inserted downstream of a strong eukaryotic promoter from cytomegalovirus (CMV). PcDNA3 is a commercially available eukaryotic expression vector (Invitrogen).
FIG. 2 shows a culture of EPC cells (passaged fish cells) transfected with a pcDNA3-BU1. BU1 is a ScAb gene construct encoding a recombinant antibody which is able to neutralise the fish pathogenic rhabdovirus, VHSV. BU1 carries a part of the human kappa light chain gene as a residue or tag. Twelve days after the date of transfection the cells were fixed and stained immunochemically using horseradish peroxidase-conjugated rabbit antibody to human kappa light chain (HRP-Rabbit anti-kappa) for the detection of cells containing ScAb. These cells give a positive response and are darker than the remaining cells; and
FIG. 3 shows a histological section of muscle tissue sampled from a fish twelve days after intramuscular injection of pcDNA3-BU1. The section was stained immunochemically using HRP-rabbit anti-kappa for the detection of ScAb. Several cells turned out positive (arrow heads) along the regenerating needle track (injection site) arrowed.
Gene Map

The following gene map is the DNA sequence of the construct comprising a single chain antibody gene (BU1) inserted into E. coli pcDNA3 plasmid (Invitrogen) used in the Example described below.


1	cagtgtgcta acatgagggc agtgtgtttg atgctgactg
	ccttattgat

51	gctggaatat gtgtgccgga gtgaccaggt gcagctgcag
	gagtcaggac

101	ctggcctcgt gaaaccttct cagtctctgt ctctcacctg
	ctctgtcact

151	ggctactcca tcaccagtgg ttattactgg acctggatcc
	ggcagtttcc

201	aggaaataaa ctggaatgga tgggctacat aagctacgac
	ggtaccaata

251	actacaaccc atctctcaca aatcgaatct ccatcactcg
	tgacacatct

301	aagaaccagt ttttcctgaa gttgaaatct gtgactactg
	aggacacagc

351	tacatattac tgtgtaagag ggatctacta tggtaacgac
	tggtttgctt

401	actggggcca agggaccacg gtcaccgtct cctcagaagg
	caaatcttct

451	ggctctggct ctgaatctaa agtggatgac atcgagctca
	cccagtctcc

501	tgcctcccag tctgcatctc tgggagaaag tgtcaccatc
	acatgcctgg

551	caagtcagac cattggtaca tggttagcat ggtatcaaca
	gaaaccaggg

601	aaatctcctc agctcctgat ttatgctgca accagtttgg
	cagatggggt

651	cccatcaagg ttcagtggta gtggatctgg cacaaaattt
	tctttcaaga

701	tcagcagcct acaggctgaa gattttgtaa gttattactg
	tcaacaactt

751	tacagtactc cgtacacgtt cggagggggg accaagctcg
	agatcaaacg

801	gactgtggct gcaccatctg tcttcatctt cccgccatct
	gatgagcagt

851	tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa
	cttctatccc

901	agagaggcca aagtacagtg gaaggtggat aacgccctcc
	aatcgggtaa

951	ctcccaggag agtgtcacag agcaggacag caaggacagc
	acctacagcc

1001	tcagcagcac cctgacgctg agcaaagcag actacgagaa
	acacaaagtc

1051	tacgcctgcg aagtcaccca tcagggcctg agttcgcccg
	tcacaaagag

1101	cttcaaccgc ggagagtcat aagttagata tccat

The BU1 insert (ScAb gene construct) is encoded by nucleotides 10 to 1125. The coding region nucleotides are 13 to 1122.
The above identified sequence can be found in the Genebank, the Accession Number is AF302092.

EXAMPLE

Single chain antibody genes were prepared according to the procedure described by McGregor et al; Spontaneous Assembly of Divalent Single Chain Antibody Fragments in E-Coli; Mol. Immunol, February 31(3) pp 219 to 226; 1994. In short, the variable domains of the immunoglobulin H and L chain genes were cloned from hybridoma cell lines producing monoclonal antibodies to the fish pathogenic rhabdovirus viral haemorrhagic septicaemia virus (VHSV). The H and L chain variable domains were linked by a gene sequence encoding a 14 amino acid linker to generate a single chain antibody (ScAb) gene. As a tag to allow specific detection, the human kappa light chain constant domain gene was included at the 3′ end of the gene. In order to ensure secretion of the ScAb polypeptides in eukaryotic cells, the nucleotide sequence encoding the 20 amino acid signal peptide of rainbow trout transforming growth factor beta (TGF-beta) was added at the 5′ end of the gene.
The gene construct was inserted by blunt-end ligation into the eukaryotic expression vector pcDNA3 (Invitrogen) in the EcoR I site in the polylinker downstream of a cytomegalovirus (CMV) promoter (see FIG. 1). As a negative control in transfection experiments with cell cultures and immunoprotection trials in fish, the pcDNA3 plasmid without insert was used. Plasmid DNA was purified from overnight cultures of E. coli by use of commercial kits for anion-exchange chromatography as recommended by the supplier (Qiagen).
Other molecular biology procedures used were as followed by Sambrook et al in Molecular Cloning; A Laboratory Manual, Second Addition, Cold Spring Harbor Laboratory, USA, (1989). The variable domain genes from a hybridoma cell line secreting the VHSV-neutralising monoclonal antibody 3F1H10 were used. Cloning and sequencing of the variable domain genes has already been described. In the case of antibody 3F1H10, two amino acids substitutions were made to the H-chain (Asn35a to Thr and Lys64 to Thr). The ScAb carrying the variable domains of antibody 3F1H10 was called BU1.
Passaged fish cells designated (EPC) were transfected with an anionic transfection reagent (Superfect, Qiagen). Four to six days after transfection cell culture supernatant were harvested and analysed for antibody reactivity to VHSV. After removal of the supernatant, the cells remaining attached to the bottom of the cell culture wells were fixed in 80% cold acetone and stained by immuno-peroxidase using horseradish peroxidase-conjugated rabbit antibody to human kappa light chain (HRP-Rabbit anti-kappa) (DAKO, Denmark) in order to detect cells expressing ScAb. The effect of transfection on the susceptibility of the cell cultures to VHSV different doses of live VHSV was examined by adding the different doses to wells with cultures of transfected cells four days after transfection and the development of cytopathogenic effects (CPE) was recorded thereafter.
Injection of Plasmid DNA into Fish
Disease free rainbow trout fingerlings, average weight 4.5 g, were anaesthetised with 0.001% benzokaine and given two 25 μl injections of 20 μg plasmid DNA each, in the epaxial muscles below the dorsal fin. The fish were afterwards kept in groups of approximately 150 individuals in 120-liter tanks supplied with running tap water. The fish were fed ad libitum with commercial fish feed. Mean water temperature was 16° C. Injected plasmid constructs included the pcDNA3 vector without insert, and pcDNA3 carrying the ScAb BU1 gene construct (pcDNA-BU1) respectively.
Immunohistochemical Analysis for Expression of ScAb in Infected Fish
Twelve days after injection of plasmid DNA, 10 fish were sampled for each plasmid construct. After termination of the fish a section of muscle tissue was excised from the site of injection. The tissue was fixed in 10% phosphate buffered formalin and analysed by immunohistochemistry. Horseradish peroxidase-conjugated rabbit immunoglobulin (Ig) to human kappa light chain (HRP-rabbit anti kappa) (Dako, Denmark) was used for detection of expressed ScAb.
Sampling of Plasma from Fish
Blood samples were collected 12 days after injection of plasmid DNA from fish not exposed to VHSV. Due to the small size of the fish, sampling was performed with heparin-treated capillary tubes after cutting off the posterior fin of fully anaesthetised fish. The fish were terminated immediately afterwards. The blood samples were centrifuged at 5000×g and plasma samples were collected and stored at −80° C. until analysed.
Serological Examination for VHSV-Reactive ScAbs
Supernatant from transfected cell cultures and plasma samples from DNA-injected fish, were examined for anti-VHSV reactive ScAbs by a plaque-neutralisation (50% PNT) assay and by an enzyme-linked immunosorbent assay (ELISA).
The ELISA assay was performed in 96-well microtitre plates coated with purified VHSV. Bound ScAb's were detected with HRP-Rabbit anti-kappa. In order to demonstrate that the virus-neutralising activity detected in the trout plasma was due to the ScAbs produced by the fish and not by trout antibodies, two variants of the 50% PNT assay were also applied. One variant included parallel examination of the neutralising activity against the virulent VHSV3592B and a neutralisation resistant variant of VHS 3592B (VHSV DK-3542B) selected by cultivating virus in the presence of the neutralising Mab 3F1A2 which is highly similar to Mab 3F1H10. The other variant involved pre-incubation of the trout plasma with rabbit antibodies to human kappa light chain or with rabbit antibodies to trout immunoglobulin before incubation with virus. The 50% PNT microplate assay was performed as described by Olesen and Jørgensen in Detection of neutralising antibody to Egtved virus in rainbow trout by plaque neutralising with complement addition, J. Appl Ichthyol, Volume 2, pages 35 to 41.
Immunoprotection Trials in Fish
Eleven days after injection of the plasmid, groups of fish were exposed to (challenged with) the virulent VHSV DK-3592β isolate by immersion in water containing 100 000 50% tissue-culture infective doses per ml. Challenge was performed in 8-liter aquaria with 25-31 fish in each. Three replicate aquaria was included for each plasmid construct. Dead fish were afterwards daily recorded and collected. Dead fish from all tanks were analysed virologically for the presence of VHSV. Mean water temperature was 16° C. from the time of injection to immediately before challenge. At challenge, the fish were adapted to a water temperature of 12° C. and this temperature was kept throughout the 20 day challenge period.
Immunochemical Detection of Expressed ScAb in cell Culture and in Fish
It was found that after immuno-peroxidase staining using the HRP-rabbit anti-human kappa, single cells expressing ScAb could be detected in EPC cell cultures transfected with the plasmid construct pcDNA3-BU1 (FIG. 2), whereas no positive cells were found in cultures transfected with pcDNA3 without insert. Similarly, expression of ScAb could be demonstrated in muscle sections from injected fish (FIG. 3). No positive cells were found in fish injected with pcDNA3 without insert.
Interference of ScAbs with Propagation of VHSV in Cell Culture

When monolayers of epithelial cell line of cap cell cultures were inoculated with VHSV four days after transfection, development of cytopathogenic effect (CPE) as a result of multiplication of VHSV was highly different in cultures transfected with pcDNA3 compared to cell cultures transfected with pcDNA3-BU1. In the latter case only certain plaques of cells became infected and died and there was no further development of CPE in the 8-day observation period. In contrast, when cultures transfected with pcDNA3 were inoculated, all cells became infected and were destroyed within 3-6 days as in a normal propagation of VHSV in EPC cells (Table 1).

TABLE 1


Susceptibility of transfected EPC cell cultures to VHSV

	Plasmid Construct used for	Cytopathogenic effect upon
	Transfection	inoculation with VHSV*

	pCDNA3	Complete destruction of cell
		layer
	pCDNA3-BU1	Plaques

	*Concentrations of VHSV: 10²-10³TCID-50/ml cell culture medium.

Detection of ScAbs to VHSV in the Fish

When the plasma from injected fish was analysed by ELISA for ScAbs recognising VHSV, a strong reaction was found in plasma from fish injected with pcDNA3-BU1. No reactivity was detected in plasma from fish injected with pcDNA3 without insert. As indicated in Table 2, the limited amounts of plasma available made it necessary to perform the analysis on pools of five individuals. The 50% PNT analysis was performed on individual plasma samples. All 10 individuals injected with pcDNA3-BU1 neutralised VHSV, whereas no neutralising activity was detected in plasma from fish injected with the pcDNA3 (Table 3). When plasma from fish injected with pcDNA3-BU1 was preincubated with Rabbit anti-human kappa before testing in 50% PNT, the neutralising activity was eliminated, whereas no effect was observed upon pre-incubation with normal rabbit serum or with rabbit serum to trout Ig (Table 4). The neutralising activity of a positive trout serum control was unaffected by pre-incubation with normal rabbit serum and with rabbit anti-human kappa, but was highly reduced upon pre-incubation with rabbit serum to trout Ig (Table 4). As with the parent monoclonal antibody 3F1H10, plasma samples from fish injected with pcDNA3-BU1 could neutralise the virulent VHSV DK-3592β isolate, but not a neutralisation escape-mutant (not shown).

TABLE 2


Antibody reactivity in fish plasma: ELISA

		Reactivity with VHSF
	Injected	(A-496 mm)

Fish No. *	Plasmid	Dilution: 1/10	Dilution: 1/80

36529	pCDNA3	0	0
36686		0	0
36844	pCDNA3-BU1	3	1
16-20		3	1

* The plasma samples were analysed in pools of 5 individuals.

TABLE 3


Antibody reactivity in fish plasma: Neutralisation of VHSV

Fish No. *	Injected Plasmid	PNT-titres **

36534	pCDNA3	<10
36849	pCDNA3-BU1	160-640

* Plasma samples were analysed individually.
** Titres represent the reciprocal value of plasma dilutions reducing the number of plaques to approximately 50% compared to a control well without antibody/plasma.

TABLE 4


Effect of preincubation of trout plasma
with rabbit antibodies on PNT-titres*

PNT-titres

			Rabbit to
	Injected	Normal	human chain	Rabbit to
Fish No.	Reagent	rabbit	kappa	trout Ig

21-30 (1	pCDNA3-BU1	640	<40	320-640
pool)
Positive	Killed VHSV	>10240	>10240	320
trout serum
A7.1

*In order to allow detection of neutralising trout antibodies, trout complement was included as described above.

Infection Trial

When challenged with VHSV DK-3592B 11 days after injection of plasmid DNA, most of the fish injected with pcDNA3-BU1 survived whereas high mortalities were observed among fish injected with pcDNA3 (Table 5).

TABLE 5

Protection against VHSV

Accumulated mortality 20

days post challenge (mean of

Injected Plasmid triplicate tanks)

pCDNAB 81%

pCDNA3-BU1 6%
To our knowledge, this is the first report demonstrating establishment of protective immunity to an infectious pathogen in higher vertebrates by administration of genes encoding pathogen specific single chain FV antibodies. The protective activity of the pcDNA-BU1 construct fully correlated with the occurrence of neutralising anti-VHSV ScAbs in the plasma of injected fish, and although involvement of non-specific mechanisms cannot be completely excluded, it appears likely that the produced BU1 ScAb has been the major cause of protection following injection of the pcDNA3-BU1 plasmid DNA. Accordingly, in a later experiment including challenge of the fish with a virus isolate not recognised by the recombinant antibody fragment encoded by pcDNA-BU1, no protection was obtained.
In contrast to DNA-vaccines, including anti-idiotype vaccines, the administration of plasmid borne genes in this instance do not involve specific activation of the immune system in the individual. The principle is simply that single chain FV antibody polypeptides produced by the cells that take up the administered plasmid will be systemically distributed by the body fluids and protect the individual if infection with the pathogen occurs. This corresponds to the mechanism of prophylaxis against infectious diseases in humans through administration of antiserum or immunoglobulin from immunised donors or animals, but without side effects such as risk of concomitant transfer of infectious diseases or induction of hypersensitivity following repeated administrations. In order to avoid the pathogen variability overcoming the immunity established by the plasmid, practical use may involve administration of plasmids encoding genes of single chain variable fragments to several different epitopes of the pathogen or single chain FV antibody gene-expression library towards a given pathogen.
The principle of genetic immunoprophylaxis according to the invention can be extended to mammals and to humans in particular as it is a valuable tool for transient protection of individuals such as travelers against exposure to pathogens or toxins where no efficient vaccines are available. Similarly, the invention may be used for induction of the synthesis of antibodies of a desired specificity for use in immunodeficient individuals. Also the nucleic acid construct of the present invention could be used in individuals that produce an allergic response to certain allergens, such as pollen. In this connection, production or induction of antibody fragments to those allergens may be used for prevention of an allergic reaction.
Beside the prophylactic aspects of the invention, plasmid constructs carrying genes encoding pathogen/disease antigen specific single chain FV antibodies are of therapeutic use in certain diseases wherein the host immune system itself is unable to produce antibodies with the necessary activity.

Claims

1. A pharmaceutical composition for protection of an animal against a disease-causing agent, the composition comprising a non-infectious nucleic acid construct encoding a recombinant antibody to that agent.

2. A pharmaceutical composition according to claim 1 wherein the animal is selected from a mammal or a fish.

3. A pharmaceutical composition according to claim 1 wherein the animal has a deficient immune system.

4. A pharmaceutical composition according to claim 1 wherein the disease-causing agent is selected from a pathogen, an allergen or a toxic substance.

5. A pharmaceutical composition according to claim 1 wherein the protection is prophylactic.

6. A pharmaceutical composition according to claim 1 wherein the encoded recombinant antibody is derived from an antibody raised against the disease-causing agent.

7. A pharmaceutical composition according to claim 1 wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.

8. A pharmaceutical composition according to claim 1, wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.

9. A pharmaceutical composition according to claim 1 comprising genes encoding antibody molecules to several different epitopes of the disease-causing agent.

10. A pharmaceutical composition according to claim 1 comprising a gene-expression library encoding antibodies to the disease-causing agent.

11. A pharmaceutical composition according to claim 10 wherein the gene expression library encodes single-chain antibody molecules to the disease-causing agent.

12. A pharmaceutical composition according to claim 1 wherein the encoded recombinant antibody is a virus-neutralising antibody.

13. A pharmaceutical composition according to claim 12 wherein the encoded virus-neutralising antibody is single chain molecule.

14. A pharmaceutical composition according to claim 1 including a nucleic acid construct encoding a viral haemorrhagic septicaemia virus VHSV-neutralising monoclonal antibody 3F1H10 with two amino acids substituents in the H-chain gene respectively Asn 35a to Thr and Lys 64 to Thr and with the secretion signal of rainbow trout transforming growth factor (TGF-beta) added to the 5′ end of the gene.

15. A pharmaceutical composition according to claim 6 wherein when the disease-causing agent is an allergen the antibody molecule is derived from an antibody raised against IgE molecules.

16. A pharmaceutical composition according to claim 1 wherein the nucleic acid construct is formed from DNA.

17. A pharmaceutical composition according to claim 1 wherein the composition is in the form of a vaccine, dosage form, cream, ointment, liquid or paint.

18. A pharmaceutical composition according to claim 17 wherein the composition is for delivery by injection, spray or gene gun.

19. A method of conferring protection against a disease caused by a pathogen, an allergen or a toxin on an animal comprising administering thereto a pharmaceutical composition of claim 1.

20. (canceled)